Datuk Franki Anthony Dass
Sime Darby Berhad
Datuk Franki Anthony Dass who started his career in Kumpulan Guthrie Berhad in 1980 as an Assistant Manager, has over 30 years of experience in the plantation industry. After various postings across Malaysia, Mr. Dass assumed the post of General Manager of PT Minamas in Indonesia in 2002. He subsequently became the Chief Operating Officer of PT Minamas in 2004, before assuming the post of Chief Executive Officer in 2007. He was appointed as the Executive Vice President of the Plantation Division in December 2010. Mr. Dass holds a Bachelor of Science degree in Agriculture from Universiti Pertanian Malaysia (now Universiti Putra Malaysia) and has attended various management and MBA programs with the Malaysian Institute of Management (MIM) and the Asian Institute of Management (AIM).
E. William Radany, Ph.D.
President and CEO
E. William Radany has over 30 years experience in the biotechnology industry. Prior to joining Verdezyne in 2008, he was the President and CEO of High Throughput Genomics, Inc., a provider of novel array-based gene expression assay technology for the life science industry. Previously, Dr. Radany was President of Biacore and founder and CEO of NeoGenex. Dr. Radany has held executive positions at Xencor, Caliper Technologies and Stratagene, where he helped establish business relationships with major pharmaceutical and biotechnology companies. Dr. Radany has spoken at numerous conferences and has invented several patents over the past 30 years. Dr. Radany received his Bachelor of Science degree in Cell Biology from Colorado State University and a Ph.D. in Biochemistry/Physiology from the University of Wyoming.
Sime Darby Berhad
Ms. Ramachandran joined Sime Darby in April 2011 as the Chief Financial Officer of the Plantation Division. Prior to assuming the post, she was an Executive Director of PricewaterhouseCoopers Malaysia. Ms. Ramachandran has over 18 years of experience in providing audit and business advisory services to clients, both local and publicly listed companies as well as multinationals, in various industries. Her current role now includes the financial oversight of companies within the Plantation Division. She is a Fellow of the Chartered Association of Certified Accountants and a member of the Malaysian Accounting Standards Board Working Group on ED 50 Biological Assets (IAS 41).
Drew Senyei, M.D.
Dr. Senyei is a managing director at Enterprise Partners where he leads the life science practice. Dr. Senyei focuses on investments in pharmaceuticals, biopharmaceuticals, diagnostics, medical devices and consumer healthcare. He has served on over 25 public and private boards including Adeza Biomedical, NuVasive, Corixa Corp., Ligand Pharmaceuticals, Nanogen, Inc., and Discovery Partners. He currently sits on the boards of Enterprise portfolio companies including: Anaborex, Ascenta Therapeutics, Celladon, Ceula, Complete Genomics, Genoptix, Ophthonix, and TargeGen.
Meghan Sharp, Ph.D.
Dr. Sharp is a member of BP’s corporate venture team. Investments span the BP Group, focused on emerging, strategic technologies in five areas: bioenergy and biomaterials; energy efficiency and storage; carbon management; renewable power; and oil and gas. Dr. Sharp focuses on biobased investments for the team and serves on the board of Chromatin Inc., Biosynthetic Technologies, Verdezyne, and Taxon Biosciences. She received her Ph.D. in microbial genetics from the University of California, San Francisco, performed post-doctoral work in plant genetics at the University of Chicago and the Carnegie Institution of Washington at Stanford University, and received her MBA from Columbia University.
OVP Venture Partners
Mr. Waite has more than 25 years of experience in both the management and investment sides of emerging growth companies. In 1987, he left his post as General Partner at Hambrecht & Quist Venture Partners to join OVP Venture Partners. Prior to that, he was in marketing and sales management at Cobe Laboratories, Inc. in its cardiovascular medical products division. Mr. Waite earned an AB in History from Kenyon College and an MBA from Harvard University.